0001209191-23-060008.txt : 20231229 0001209191-23-060008.hdr.sgml : 20231229 20231229163439 ACCESSION NUMBER: 0001209191-23-060008 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231228 FILED AS OF DATE: 20231229 DATE AS OF CHANGE: 20231229 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lowrance David L CENTRAL INDEX KEY: 0001408498 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32157 FILM NUMBER: 231528149 MAIL ADDRESS: STREET 1: 422 WILLIAM WALLACE DRIVE CITY: FRANKLIN STATE: TN ZIP: 37064 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Savara Inc CENTRAL INDEX KEY: 0001160308 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 841318182 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6836 BEE CAVE ROAD STREET 2: BUILDING 3, SUITE 201 CITY: AUSTIN STATE: TX ZIP: 78746 BUSINESS PHONE: 51285113796 MAIL ADDRESS: STREET 1: 6836 BEE CAVE ROAD STREET 2: BUILDING 3, SUITE 201 CITY: AUSTIN STATE: TX ZIP: 78746 FORMER COMPANY: FORMER CONFORMED NAME: Mast Therapeutics, Inc. DATE OF NAME CHANGE: 20130312 FORMER COMPANY: FORMER CONFORMED NAME: ADVENTRX PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030613 FORMER COMPANY: FORMER CONFORMED NAME: BIOKEYS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010928 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-12-28 0 0001160308 Savara Inc SVRA 0001408498 Lowrance David L ONE SUMMIT SQUARE, 1717 LANGHORNE NEWTOWN ROAD, SUITE 300 LANGHORNE PA 19047 0 1 0 0 CHIEF FINANCIAL OFFICER 0 Common Stock 2023-12-28 4 S 0 10000 4.7131 D 342355 D Represents shares sold to satisfy tax liability upon the vesting of restricted stock units. The price is a weighted average sales price. The sale prices ranged from $4.70 to $4.795. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. /s/ David Lowrance 2023-12-29